sb 203580 has been researched along with Exertional Heat Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boumendjel, A; Carroll, R; Godin-Ribuot, D; Joyeux, M; Ribuot, C; Yellon, DM | 1 |
| Atluri, S; Kukreja, RC; Tejero-Taldo, MI; Tekin, D; Xi, L; Zhao, T | 1 |
2 other study(ies) available for sb 203580 and Exertional Heat Illness
| Article | Year |
|---|---|
SB 203580, a mitogen-activated protein kinase inhibitor, abolishes resistance to myocardial infarction induced by heat stress.
Topics: Animals; Blotting, Western; Enzyme Inhibitors; Heat Stress Disorders; Heat-Shock Proteins; Hemodynamics; HSP72 Heat-Shock Proteins; Imidazoles; Mitogen-Activated Protein Kinases; Myocardial Infarction; Pyridines; Rats; Reperfusion Injury; Ventricular Function, Left | 2000 |
Mitogen-activated protein kinases mediate heat shock-induced delayed protection in mouse heart.
Topics: Animals; Enzyme Inhibitors; Heat Stress Disorders; Imidazoles; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardial Ischemia; Phosphorylation; Pyridines; Signal Transduction | 2001 |